Ibrexafungerp citrate - Generic Drug Details
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
What are the generic sources for ibrexafungerp citrate and what is the scope of freedom to operate?
Ibrexafungerp citrate
is the generic ingredient in one branded drug marketed by Scynexis and is included in one NDA. There are four patents protecting this compound. Additional information is available in the individual branded drug profile pages.Ibrexafungerp citrate has twenty-five patent family members in eighteen countries.
One supplier is listed for this compound.
Summary for ibrexafungerp citrate
| International Patents: | 25 |
| US Patents: | 4 |
| Tradenames: | 1 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| DailyMed Link: | ibrexafungerp citrate at DailyMed |
Pharmacology for ibrexafungerp citrate
| Drug Class | Triterpenoid Antifungal |
| Mechanism of Action | Glucan Synthase Inhibitors |
US Patents and Regulatory Information for ibrexafungerp citrate
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Scynexis | BREXAFEMME | ibrexafungerp citrate | TABLET;ORAL | 214900-001 | Jun 1, 2021 | RX | Yes | Yes | See Plans and Pricing | See Plans and Pricing | Y | See Plans and Pricing | |||
| Scynexis | BREXAFEMME | ibrexafungerp citrate | TABLET;ORAL | 214900-001 | Jun 1, 2021 | RX | Yes | Yes | See Plans and Pricing | See Plans and Pricing | Y | Y | See Plans and Pricing | ||
| Scynexis | BREXAFEMME | ibrexafungerp citrate | TABLET;ORAL | 214900-001 | Jun 1, 2021 | RX | Yes | Yes | See Plans and Pricing | See Plans and Pricing | Y | Y | See Plans and Pricing | ||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for ibrexafungerp citrate
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Poland | 3247711 | See Plans and Pricing | |
| World Intellectual Property Organization (WIPO) | 2010019204 | See Plans and Pricing | |
| Eurasian Patent Organization | 201791645 | НОВЫЕ СОЛИ И ПОЛИМОРФЫ SCY-078 | See Plans and Pricing |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2023 - 2024
NCE-1 Patent Challenge Dates 2023 - 2024
ClinicalTrialExchange - Connecting volunteers and trials
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2023, www.DrugPatentWatch.com.
Follow DrugPatentWatch:
